Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Bind Therapeutics
Bind Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
Resolving capping issues in tablet manufacturing
Natoli explores the various causes of capping and the methods to prevent it
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
PeptiDream to collaborate with BIND Therapeutics
To investigate the use of the firm's macrocyclic peptides as the targeting ligand on BIND’s Accurin nanoparticles
Research & Development
BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines
Collaboration will focus on combining BIND\'s technology with Roche\'s proprietary therapeutic payloads and targeting ligands
You need to be a subscriber to read this article.
Click here
to find out more.
Drug Delivery
Helping the delivery of biotech-based therapies
Modern biotech-derived medicines require new methods to aid targeted delivery. Dr Sarah Houlton, looks at some of the novel nano-based technologies that are getting results
Research & Development
AstraZeneca and Bind Therapeutics sign cancer nanomedicine agreement
Bind could be eligible for US$200m in payments through Accurin deal
Research & Development
Pfizer signs deal with Bind Therapeutics
To develop and commercialist Accurins using Bind nanoengineering technology
Subscribe now